Evidence map›Paper›PMID 39261334›Full record

ArticleMikrochimica acta2024

Platinum-perovskite nanocomposite-based Exosensor for specific detection of prostate cancer in clinical settings.

Ehsan Dezhakam, Elham Mahmoudi, Abdolhossein Naseri, Reza Rahbarghazi, Ibrahim Isildak, Balal Khalilzadeh, Aligholi Niaei, Nagihan Delibas, Ali Coruh

Abstract read
PubMed Publisher
In one paragraph

Article in Mikrochimica acta, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ehsan DezhakamDepartment of Analytical Chemistry, Faculty of Chemistry, University of Tabriz, Tabriz, Iran.
Elham MahmoudiCatalyst and Reactor Research Lab, Department of Chemical & Petroleum Engineering, University of Tabriz, Tabriz, Iran.
Abdolhossein NaseriDepartment of Analytical Chemistry, Faculty of Chemistry, University of Tabriz, Tabriz, Iran. ab.naseri@gmail.com.
Reza RahbarghaziStem Cell Research Center (SCRC), Tabriz University of Medical Sciences, Tabriz, Iran.
Ibrahim IsildakDepartment of Bioengineering, Faculty of Chemistry-Metallurgy, Yildiz Technical University, 34220, Istanbul, Turkey.
Balal KhalilzadehStem Cell Research Center (SCRC), Tabriz University of Medical Sciences, Tabriz, Iran. balalkhalilzadeh@gmail.com.
Aligholi NiaeiCatalyst and Reactor Research Lab, Department of Chemical & Petroleum Engineering, University of Tabriz, Tabriz, Iran.
Nagihan DelibasDepartment of Physics, Faculty of Science, University of Sakarya, Sakarya, Turkey.
Ali CoruhDepartment of Physics, Faculty of Science, University of Sakarya, Sakarya, Turkey.

Funding

Tabriz University of Medical Sciences 73720
6 · The paper itself

Abstract

Exosomes, extracellular vesicles (EVs) with an average size of 50-150 nm, transfer various biomolecules and exchange signaling molecules between cells in a paracrine manner. Molecular investigations have revealed that EVs can reflect real-time metabolic changes in normal- and cancer-origin cells and thus harbor valid diagnostic biomarkers. Despite these advantages, the detection of low concentrations of cancer cell EVs in biological fluids is still a great challenge. Here, a new electrochemical Exosensor based on platinum-perovskite is developed for the direct detection of EVs using a biotinylated monoclonal CD63 antibody as a capture element. The label-free method exhibited higher sensitivity with a lower limit of quantification of 2000 EVs/µL with a dynamic linear range (LDR) of 2000 to 14,000 EVs/μL compared with other available methods. To enhance the selectivity of detection, EVs were simultaneously sandwiched between secondary antibodies of PSA (prostate-specific antigen), as an FDA-approved prostate cancer biomarker. Data indicated that this Exosensor can distinguish normal and cancer EVs in samples from healthy individuals and prostate cancer patients. Taken together, this technology offers a unique approach to label-free quantification of EVs and cancer detection in the early stages.

Indexed as

NanocompositesPlatinumProstatic NeoplasmsBiomarkers, TumorBiosensing TechniquesElectrochemical TechniquesExosomesHumansLimit of DetectionMaleProstate-Specific AntigenTetraspanin 30Biomarkers, TumorPlatinumProstate-Specific AntigenTetraspanin 30Differential pulse voltammetryElectrochemical ExosensorExosomesExtracellular vesiclesModified glassy carbon electrodePerovskiteProstate-specific antigen

Identifiers

PMID39261334

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.